French drugmaker Ipsen today released final results from the Phase III CheckMate -9ER trial of Cabometyx (cabozantinib) in ...

A former executive at French drugmaker Ipsen was sentenced on Thursday to two months in a U.S. prison for illegally trading ...

A former Ipsen executive, Dishant Gupta, was sentenced to two months in prison for insider trading. He illegally profited ...

Ipsen has entered an exclusive worldwide licensing agreement with Biomunex Pharmaceuticals for BMX-502, a first-in-class bispecific antibody designed to engage and activate mucosal-associated ...

(1) Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds (Article 10). * Gross total = total number of ...

Ipsen (OTCPK:IPSEY) has secured exclusive global rights for the development and commercialization of STRO-003, an antibody-drug conjugate, from Sutro Biopharma (NASDAQ:STRO), completing the final ...

Ipsen has taken rights to PPAR agonist elafibranor as a treatment for primary biliary cholangitis – a chronic, autoimmune disease in which bile ducts in the liver are gradually destroyed causing ...

Ipsen is a growing biopharma company that combines a dynamic, biotech mindset with the resources that come from having 5,400 employees and a direct presence in more than 30 countries. This ...

Ipsen has suffered a setback in its marathon effort to bring palovarotene to market for ultra rare disease fibrodysplasia ossificans progressiva (FOP), after EU advisors recommended against approval.

In a report released today, Lucy Codrington from Jefferies maintained a Hold rating on Ipsen (0MH6 – Research Report), with a price target of ...

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with ...